Publication

Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis

Arends, S., Wink, F., Veneberg, J., Bos, R., van Roon, E., van der Veer, E., Maas, F. & Spoorenberg, A., 5-Jul-2020, In : British Journal of Clinical Pharmacology. 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Arends, S., Wink, F., Veneberg, J., Bos, R., van Roon, E., van der Veer, E., Maas, F., & Spoorenberg, A. (2020). Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.14431

Author

Arends, Suzanne ; Wink, Freke ; Veneberg, Joyce ; Bos, Reinhard ; van Roon, Eric ; van der Veer, Eveline ; Maas, Fiona ; Spoorenberg, Anneke. / Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis. In: British Journal of Clinical Pharmacology. 2020.

Harvard

Arends, S, Wink, F, Veneberg, J, Bos, R, van Roon, E, van der Veer, E, Maas, F & Spoorenberg, A 2020, 'Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis', British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.14431

Standard

Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis. / Arends, Suzanne; Wink, Freke; Veneberg, Joyce; Bos, Reinhard; van Roon, Eric; van der Veer, Eveline; Maas, Fiona; Spoorenberg, Anneke.

In: British Journal of Clinical Pharmacology, 05.07.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Arends S, Wink F, Veneberg J, Bos R, van Roon E, van der Veer E et al. Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis. British Journal of Clinical Pharmacology. 2020 Jul 5. https://doi.org/10.1111/bcp.14431


BibTeX

@article{98403d31fc8049f5b68bd4f46f84c371,
title = "Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis",
abstract = "Aims: To evaluate whether 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements has an effect on lumbar spine and hip bone mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis factor-α inhibitors or receiving conventional treatment. Secondly, to explore the development of radiographic vertebral fractures. Methods: Patients from the Groningen Leeuwarden AS cohort receiving bisphosphonates based on clinical indication and available 2-year follow-up BMD measurements were included. BMD of lumbar spine (L1–L4) and hip (total proximal femur) were measured using dual-energy X-ray absorptiometry. Spinal radiographs (Th4–L4) were scored for vertebral fractures according to the Genant method. Results: In the 20 included patients (median 52 years, 14 males), lumbar spine and hip BMD Z-scores increased significantly; median from −1.5 (interquartile range [IQR] −2.2 to 0.4) to 0.1 (IQR −1.5 to 1.0); P <.001 and median from −1.0 (IQR −1.6 to −0.7) to −0.8 (IQR −1.2 to 0.0); P =.006 over 2 years, respectively. In patients also treated with tumour necrosis factor-α inhibitors (n = 11), lumbar spine and hip BMD increased significantly (median 2-year change +8.6% [IQR 2.4 to 19.6; P =.009] and +3.6% [IQR 0.7–9.0; P =.007]). In patients on conventional treatment (n = 9), lumbar spine BMD increased significantly (median 2-year change +3.6%; IQR 0.7 to 9.0; P =.011) and no improvement was seen in hip BMD (median −0.6%; IQR −3.1 to 5.1; P =.61). Overall, younger AS males with limited spinal radiographic damage showed most improvement in lumbar spine BMD. Four mild radiographic vertebral fractures developed in 3 patients and 1 fracture increased from mild to moderate over 2 years in postmenopausal women and middle-aged men. Conclusion: This explorative observational cohort study in AS showed that 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements significantly improves lumbar spine BMD. Mild radiographic vertebral fractures still occurred.",
keywords = "ankylosing spondylitis, bisphosphonates, bone mineral density, tumour necrosis factor-alpha inhibitors, vertebral fractures, VERTEBRAL FRACTURES, PAMIDRONATE, ALENDRONATE, PREVALENCE, INFLIXIMAB, INCREASES, THERAPY, RISK, MG",
author = "Suzanne Arends and Freke Wink and Joyce Veneberg and Reinhard Bos and {van Roon}, Eric and {van der Veer}, Eveline and Fiona Maas and Anneke Spoorenberg",
note = "This article is protected by copyright. All rights reserved.",
year = "2020",
month = jul,
day = "5",
doi = "10.1111/bcp.14431",
language = "English",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley",

}

RIS

TY - JOUR

T1 - Bone mineral density improves during 2 years of treatment with bisphosphonates in patients with ankylosing spondylitis

AU - Arends, Suzanne

AU - Wink, Freke

AU - Veneberg, Joyce

AU - Bos, Reinhard

AU - van Roon, Eric

AU - van der Veer, Eveline

AU - Maas, Fiona

AU - Spoorenberg, Anneke

N1 - This article is protected by copyright. All rights reserved.

PY - 2020/7/5

Y1 - 2020/7/5

N2 - Aims: To evaluate whether 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements has an effect on lumbar spine and hip bone mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis factor-α inhibitors or receiving conventional treatment. Secondly, to explore the development of radiographic vertebral fractures. Methods: Patients from the Groningen Leeuwarden AS cohort receiving bisphosphonates based on clinical indication and available 2-year follow-up BMD measurements were included. BMD of lumbar spine (L1–L4) and hip (total proximal femur) were measured using dual-energy X-ray absorptiometry. Spinal radiographs (Th4–L4) were scored for vertebral fractures according to the Genant method. Results: In the 20 included patients (median 52 years, 14 males), lumbar spine and hip BMD Z-scores increased significantly; median from −1.5 (interquartile range [IQR] −2.2 to 0.4) to 0.1 (IQR −1.5 to 1.0); P <.001 and median from −1.0 (IQR −1.6 to −0.7) to −0.8 (IQR −1.2 to 0.0); P =.006 over 2 years, respectively. In patients also treated with tumour necrosis factor-α inhibitors (n = 11), lumbar spine and hip BMD increased significantly (median 2-year change +8.6% [IQR 2.4 to 19.6; P =.009] and +3.6% [IQR 0.7–9.0; P =.007]). In patients on conventional treatment (n = 9), lumbar spine BMD increased significantly (median 2-year change +3.6%; IQR 0.7 to 9.0; P =.011) and no improvement was seen in hip BMD (median −0.6%; IQR −3.1 to 5.1; P =.61). Overall, younger AS males with limited spinal radiographic damage showed most improvement in lumbar spine BMD. Four mild radiographic vertebral fractures developed in 3 patients and 1 fracture increased from mild to moderate over 2 years in postmenopausal women and middle-aged men. Conclusion: This explorative observational cohort study in AS showed that 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements significantly improves lumbar spine BMD. Mild radiographic vertebral fractures still occurred.

AB - Aims: To evaluate whether 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements has an effect on lumbar spine and hip bone mineral density (BMD) in ankylosing spondylitis (AS) patients starting tumour necrosis factor-α inhibitors or receiving conventional treatment. Secondly, to explore the development of radiographic vertebral fractures. Methods: Patients from the Groningen Leeuwarden AS cohort receiving bisphosphonates based on clinical indication and available 2-year follow-up BMD measurements were included. BMD of lumbar spine (L1–L4) and hip (total proximal femur) were measured using dual-energy X-ray absorptiometry. Spinal radiographs (Th4–L4) were scored for vertebral fractures according to the Genant method. Results: In the 20 included patients (median 52 years, 14 males), lumbar spine and hip BMD Z-scores increased significantly; median from −1.5 (interquartile range [IQR] −2.2 to 0.4) to 0.1 (IQR −1.5 to 1.0); P <.001 and median from −1.0 (IQR −1.6 to −0.7) to −0.8 (IQR −1.2 to 0.0); P =.006 over 2 years, respectively. In patients also treated with tumour necrosis factor-α inhibitors (n = 11), lumbar spine and hip BMD increased significantly (median 2-year change +8.6% [IQR 2.4 to 19.6; P =.009] and +3.6% [IQR 0.7–9.0; P =.007]). In patients on conventional treatment (n = 9), lumbar spine BMD increased significantly (median 2-year change +3.6%; IQR 0.7 to 9.0; P =.011) and no improvement was seen in hip BMD (median −0.6%; IQR −3.1 to 5.1; P =.61). Overall, younger AS males with limited spinal radiographic damage showed most improvement in lumbar spine BMD. Four mild radiographic vertebral fractures developed in 3 patients and 1 fracture increased from mild to moderate over 2 years in postmenopausal women and middle-aged men. Conclusion: This explorative observational cohort study in AS showed that 2 years of treatment with bisphosphonates in combination with calcium/vitamin D supplements significantly improves lumbar spine BMD. Mild radiographic vertebral fractures still occurred.

KW - ankylosing spondylitis

KW - bisphosphonates

KW - bone mineral density

KW - tumour necrosis factor-alpha inhibitors

KW - vertebral fractures

KW - VERTEBRAL FRACTURES

KW - PAMIDRONATE

KW - ALENDRONATE

KW - PREVALENCE

KW - INFLIXIMAB

KW - INCREASES

KW - THERAPY

KW - RISK

KW - MG

U2 - 10.1111/bcp.14431

DO - 10.1111/bcp.14431

M3 - Article

C2 - 32530102

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

ER -

ID: 127405914